Corvidia Therapeutics to Participate in Jefferies 2019 London Healthcare Conference and Stifel Healthcare Conference 2019
WALTHAM, Mass., Nov. 18, 2019 /PRNewswire/ -- Corvidia Therapeutics Inc., a clinical stage company focused on the research, development and commercialization of transformative therapies in cardio-renal disease, today announced the company will present at two upcoming healthcare conferences. Executives will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 7:20 a.m. - 7:50 a.m. GMT / 2:20 a.m. - 2:50 a.m. ET and the Stifel Healthcare Conference 2019 in New York City on Wednesday, November 20 at 9:10 a.m. - 9:40 a.m. ET.
About Corvidia Therapeutics Inc.
Corvidia Therapeutics is a clinical stage company focused on the research, development and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for atherosclerotic cardiovascular disease (ASCVD) and inflammation in chronic kidney disease (CKD) patients, and high triglyceride-induced acute pancreatitis (AP). Founded in 2015, Corvidia Therapeutics is headquartered in Waltham, Massachusetts. Learn more at: www.corvidiatx.com.
Press Inquiries:
McDougall Communications on behalf of Corvidia Therapeutics Inc.
Christopher Knospe, chris@mcdougallpr.com, Tel: +1 (716) 440-5580
Mike McDougall, mike@mcdougallpr.com, Tel: +1 (595) 545-1815
View original content:http://www.prnewswire.com/news-releases/corvidia-therapeutics-to-participate-in-jefferies-2019-london-healthcare-conference-and-stifel-healthcare-conference-2019-300959875.html
SOURCE Corvidia Therapeutics Inc.
Upcoming Life Sciences Events
- April 2024
- Singapore: Asia Bio Partnering Forum
- London: LSX World Congress
- May 2024
- Seoul: BIO KOREA 2024